Monday, October 3, 2022


Biotechnology News Magazine

Michael J. Klag, MD, MPH Appointed to the Doctor Evidence Medical Strategy Advisory Board

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 27, 2021

Michael J. Klag, MD, MPH, from the Johns Hopkins Bloomberg School of Public Health joins the Medical Strategy Advisory Board, expanding its expertise in public health, epidemiology, and clinical research. He joins Chair, Ameet Nathwani, MD, MRCP, DipPharmMed, MBA, and members Calum MacRae, MB, ChB, Ph.D., BSc, Frank Rockhold, Ph.D., ScM, BA, and David Tovey, MD.

Dr. Klag is a world-renowned kidney disease epidemiologist, is Dean Emeritus and Second Century Distinguished Professor at the Johns Hopkins Bloomberg School of Public Health, Trustee of the Johns Hopkins Hospital, Trustee of the David & Lucile Packard Foundation, past Chair of the Association of Schools of Public Health and previous Chair of the NIH Advisory Board on Clinical Research. “Doctor Evidence is redefining what’s possible in healthcare technology and drug discovery and, ultimately, helping to develop more rapid and effective therapeutic interventions,” said Dr. Klag, “I look forward to engaging with the MSAB and the Doctor Evidence team to advance their platform and maximize its impact to improve patient outcomes, worldwide.”

The MSAB plays an active role in guiding the Doctor Evidence road map, particularly as it relates to the use of artificial intelligence in drug repurposing and discovery, by bringing expertise and science-based evidence to bear from across the healthcare and technology spectrum.

“Mike brings tremendous epidemiological support to our Board,” Ameet Nathwani, commented. “Additionally, Mike’s appreciation for the increased importance of real-world data and phenotype clustering in the epidemiologic picture will bring invaluable contributions to our drug repurposing work.”

“The expertise in epidemiology, clinical research, and global connectivity provided by Dr. Klag represent an outstanding complement to the medical and scientific advisors on the MSAB,” stated Joseph A. Boystak, Chairman of the Board, Doctor Evidence. Boystak further noted, “I have known Dr. Klag for many years and have the privilege of working with him as a colleague on the Health Advisory Board at the Johns Hopkins Bloomberg School of Public Health.”

Doctor Evidence CEO Bob Battista commented, “Michael J. Klag, MD will be a tremendous asset to the MSAB. We’ll benefit from his years of leadership in the field of epidemiology as we expand our partnerships with pharmaceutical and life sciences companies, research institutions and patient advocacy groups.”


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine